Protagonist Therapeutics, Inc. (PTGX) Social Stream



Protagonist Therapeutics, Inc. (PTGX): $31.95

0.99 (+3.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About PTGX

$RDHL gonna put my cards on the table here….

I initially got in for the P2/3 Opaginab data with an intent to STN (Sell the News).

However, the more DD I do, the more intriguing this RDHL ticker becomes.

1) I’m seeing a lot of fundamental and technical similarities between RDHL and $PTGX when it was trading in the same area (6’s and 7’s). I felt very confident in PTGX as they had multiple shots on goal and strong, early clinical results. PTGX now trades at $48 approx. 18 months later. 7x gains over that time period. When comparing the 2 though, the nod goes to RDHL as they already have 3 drugs on the market and numerous studies in late stage clinical with more upside, parabolic potential.

2) STN on Covid, Opaginab news (if strong) would inevitably lead to seller’s remorse. Imagine selling $NVAX at $40 or $MRNA at $60. This news would be the beginning NOT the end. What comes next would be bigger than the initial news (partnerships, EUA, Wall St radar, analyst upgrades, etc.).
Sixth_Sense, published August 8, 2021

What Else are PTGX Traders Talking About?


Other tickers frequently mentioned alongside PTGX are RDHL, NVAX and MRNA.

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5726 seconds.